Jeanie B Tryggestad1, Rachana D Shah2, Barbara H Braffett3, Fida Bacha4, Samuel S Gidding5, Rose A Gubitosi-Klug6, Amy S Shah7, Elaine M Urbina7, Lorraine E Levitt Katz2. 1. Department of Diabetes and Endocrinology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA. 2. Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. 3. The Biostatistics Center, George Washington University, Rockville, Maryland, USA. 4. Department of Diabetes and Endocrinology, Baylor College of Medicine, Houston, Texas, USA. 5. FH Foundation, Pasadena, California, USA. 6. Department of Pediatric Endocrinology, Diabetes and Metabolism, Case Western Reserve University, Cleveland, Ohio, USA. 7. Division of Endocrinology, Cincinnati Children's Hospital and the University of Cincinnati, Cincinnati, Ohio, USA.
Abstract
BACKGROUND: The Treatment Options for type 2 Diabetes in Adolescent and Youth study, a randomized clinical trial of three treatments for type 2 diabetes (T2DM) in youth, demonstrated treatment failure (defined as sustained HbA1c ≥8%, or inability to wean insulin after 3 months after acute metabolic decomposition) in over half of the participants. Given that binding of mononuclear cells to vascular endothelium, initiated by cellular adhesion molecules and chemokines, is an early step in vascular injury, we sought to evaluate (a) changes in cellular adhesion molecule levels during the trial; (b) effect of diabetes treatment; and (c) association of markers with HbA1c, hypertension, hypercholesterolemia, nephropathy, and retinopathy. METHODS:Participants (n = 515 of 699) that had baseline assessment of adhesion molecules (monocyte chemoattractant protein-1 [MCP-1], vascular cell adhesion marker [VCAM], intercellular adhesion marker [ICAM], and E-Selectin) and at least one other assessment, measured at month 12, 24, or 36, were included. RESULTS: Over 1 to 3 years, significant increases in MCP-1 and decreases in VCAM (both P < .0001) concentrations were found; however, no significant interactions were identified with treatment group for any molecule. For every 1% increase in HbA1c, ICAM increased by 1.8%, VCAM by 1.5%, and E-selectin by 6.8% (all P < .0001). E-selectin increased by 3.7% and 4.2% for every 10 mm Hg increase in systolic and diastolic blood pressure, respectively (both P < .0001). ICAM was 10.2% higher and E-selectin was 15.5% higher in participants with microalbuminuria (both P < .01). There was no significant association of adhesion molecule levels with retinopathy. CONCLUSION: Concentrations of cellular adhesion molecules rise with increasing HbA1c in youth with T2DM, and are associated with blood pressure and microalbuminuria, markers of vascular injury.
RCT Entities:
BACKGROUND: The Treatment Options for type 2 Diabetes in Adolescent and Youth study, a randomized clinical trial of three treatments for type 2 diabetes (T2DM) in youth, demonstrated treatment failure (defined as sustained HbA1c ≥8%, or inability to wean insulin after 3 months after acute metabolic decomposition) in over half of the participants. Given that binding of mononuclear cells to vascular endothelium, initiated by cellular adhesion molecules and chemokines, is an early step in vascular injury, we sought to evaluate (a) changes in cellular adhesion molecule levels during the trial; (b) effect of diabetes treatment; and (c) association of markers with HbA1c, hypertension, hypercholesterolemia, nephropathy, and retinopathy. METHODS:Participants (n = 515 of 699) that had baseline assessment of adhesion molecules (monocyte chemoattractant protein-1 [MCP-1], vascular cell adhesion marker [VCAM], intercellular adhesion marker [ICAM], and E-Selectin) and at least one other assessment, measured at month 12, 24, or 36, were included. RESULTS: Over 1 to 3 years, significant increases in MCP-1 and decreases in VCAM (both P < .0001) concentrations were found; however, no significant interactions were identified with treatment group for any molecule. For every 1% increase in HbA1c, ICAM increased by 1.8%, VCAM by 1.5%, and E-selectin by 6.8% (all P < .0001). E-selectin increased by 3.7% and 4.2% for every 10 mm Hg increase in systolic and diastolic blood pressure, respectively (both P < .0001). ICAM was 10.2% higher and E-selectin was 15.5% higher in participants with microalbuminuria (both P < .01). There was no significant association of adhesion molecule levels with retinopathy. CONCLUSION: Concentrations of cellular adhesion molecules rise with increasing HbA1c in youth with T2DM, and are associated with blood pressure and microalbuminuria, markers of vascular injury.
Authors: Dana M Ciobanu; Petru A Mircea; Cornelia Bala; Adriana Rusu; Ştefan Vesa; Gabriela Roman Journal: Cytokine Date: 2019-02-01 Impact factor: 3.861
Authors: Coen D A Stehouwer; Mari-Anne Gall; Jos W R Twisk; Elisabeth Knudsen; Jef J Emeis; Hans-Henrik Parving Journal: Diabetes Date: 2002-04 Impact factor: 9.461
Authors: Jian-Jun Liu; Lee Ying Yeoh; Chee Fang Sum; Subramaniam Tavintharan; Xiao Wei Ng; Sylvia Liu; Simon B M Lee; Wern Ee Tang; Su Chi Lim Journal: J Diabetes Complications Date: 2015-02-28 Impact factor: 2.852
Authors: Edward B. Jude; Jessica T. Douglas; Simon G. Anderson; Matthew J. Young; Andrew J.M. Boulton Journal: Eur J Intern Med Date: 2002-05 Impact factor: 4.487
Authors: Caroline Kistorp; Aun Y Chong; Finn Gustafsson; Søren Galatius; Ilan Raymond; Jens Faber; Gregory Y H Lip; Per Hildebrandt Journal: Eur J Heart Fail Date: 2008-03-17 Impact factor: 15.534
Authors: Samantha Landreth; April M Teague; Mary E Jensen; Shelly Gulati; Jeanie B Tryggestad Journal: Nutr Metab Cardiovasc Dis Date: 2022-02-10 Impact factor: 4.222
Authors: Job A J Verdonschot; João Pedro Ferreira; Faiez Zannad; Stephane R B Heymans; Pierpaolo Pellicori; Hans-Peter Brunner-La Rocca; Andrew L Clark; Franco Cosmi; Joe Cuthbert; Nicolas Girerd; Beatrice Mariottoni; Johannes Petutschnigg; Patrick Rossignol; John G F Cleland Journal: Cardiovasc Diabetol Date: 2021-08-09 Impact factor: 9.951